drugset
drugset / Trial / NCT01712438

Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients

NCT01712438 ↗

Phase 3 Completed 110 enrolled Octapharma
NaSingle-groupOpen-labelTreatment

Summary

Investigate the inhibitor development rate of Human cl rhFVIII in previously untreated patients with severe Hemophilia A.

Timeline

Start
2013-02
Primary completion
2018-12-14
Completion
2019-12-20

Drugs

EvaluationDrugModalityDoseRoute
Subject simoctocog alfa Protein / enzyme biologic — —

Indications

severe hemophilia A